drugset
drugset / Trial / NCT04905914

Study Of ATRN-119 In Patients With Advanced Solid Tumors

NCT04905914 ↗

Phase 1/2 Active not recruiting 132 enrolled Aprea Therapeutics
Non-randomizedSequentialOpen-labelTreatment

Summary

The purpose of this study is to assess the safety and effectiveness of ATRN-119 through the performance of a Phase 1/2a, open-label, safety, PK, and preliminary efficacy study of oral ATRN-119 in patients with advanced solid tumors.

Timeline

Start
2023-01-09
Primary completion
2028-02
Completion
2028-02

Drugs

EvaluationDrugModalityDoseRoute
Subject ATRN-119 Unknown 50 mg Oral
Subject ATRN-119 Unknown 100 mg Oral
Subject ATRN-119 Unknown 200 mg Oral
Subject ATRN-119 Unknown 350 mg Oral
Subject ATRN-119 Unknown 400 mg Oral
Subject ATRN-119 Unknown 550 mg Oral
Subject ATRN-119 Unknown 650 mg Oral
Subject ATRN-119 Unknown 750 mg Oral
Subject ATRN-119 Unknown 800 mg Oral
Subject ATRN-119 Unknown 1100 mg Oral
Subject ATRN-119 Unknown 1300 mg Oral
Subject ATRN-119 Unknown 1500 mg Oral

Indications

neoplasm